---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Co-prescribed/Concomitant therapies. Topics: Combination treatment: 2025 international consensus guideline; Concomitant arimoclomol, levacetylleucine, and miglustat in the expanded access program; Safety of combination therapy in the expanded access program; Combination with arimoclomol or levacetylleucine in vitro: company nonclinical study. 4 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Combination treatment: 2025 international consensus guideline

> “Statement #18: Combination treatment should be considered for all patients with a confirmed diagnosis of NPC.”
> “However, available treatments have distinct mechanisms of action, making combination therapy an approach that targets multiple aspects of NPC neuropathology”
> “Despite this, it is important to note that healthcare system resource limitations often restrict access to combination treatments.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.1.2.12-2"></a>

### Concomitant arimoclomol, levacetylleucine, and miglustat in the expanded access program

> “The program permitted concomitant use of other NPC therapies, arimoclomol or levacetylleucine, after their approval, allowing evaluation of adrabetadex administered concomitantly with arimoclomol, levacetylleucine, or both.”
> “At the data cutoff of March 27, 2026, 33 participants had received adrabetadex with arimoclomol and/or levacetylleucine.”
> “All 33 participants received adrabetadex, while 27 (81.8%) received levacetylleucine, 21 (63.6%) arimoclomol, and 20 (60.6%) miglustat; 10 participants were exposed to all four therapies.”
> “A total of 5 participants received arimoclomol before U.S. approval and later added treatment with adrabetadex.”
> “Most participants initiated adrabetadex prior to complementary therapies, with arimoclomol and/or levacetylleucine frequently added after adrabetadex (when they became commercially available) rather than used instead of adrabetadex.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-2.1.2.12-3"></a>

### Safety of combination therapy in the expanded access program

> “Of participants treated with adrabetadex ± miglustat only (n=53), 90.6% experienced at least one TEAE compared to 100% of those who started adrabetadex first, followed by levacetylleucine and/or arimoclomol (n=28) and 69.7% for those who were exposed to combination therapy at any point (n=33).”
> “Safety findings were generally consistent with the established adrabetadex safety profile, with differences in treatment exposure and observation time limiting comparisons across groups.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-2.1.2.12-4"></a>

### Combination with arimoclomol or levacetylleucine in vitro: company nonclinical study

> “Other therapies for NPC including arimoclomol and N-acetyl-L-leucine (NALL; levacetylleucine), have distinct mechanisms and may address complementary aspects of the disease biology.”
> “To evaluate a) the binding interactions between adrabetadex, arimoclomol, and NALL and b) the in vitro effects of adrabetadex, arimoclomol, and NALL monotherapy, and adrabetadex in combination with arimoclomol or NALL on oligodendrocyte (OL) proliferation, synaptic network growth, and myelination of mature neurons.”
> “Combination of adrabetadex with arimoclomol or NALL achieved comparable effects at substantially lower concentrations than monotherapy, supporting mechanistic compatibility between adrabetadex and therapies with complementary mechanisms.”

Source: [Burchard et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/05/APMRF2026-P02-Nonclinical.pdf)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
